Health TrialsbyHealthPanel

Study of STIM1 Membrane Expression

ConditionAutoimmune Diseases
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-99
SponsorUniversity Hospital, Brest

About this trial

The aim of this study is to determine the expression of STIM1 in the plasma membrane of lymphocytes from patients suffering from different autoimmune diseases in order to identify new pathologies of interest presenting an over-expression of STIM1PM.

This would allow to initiate, following this study, research and development programs on the use of anti-STIM1 antibodies in these identified autoimmune diseases of interest.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Diagnosis of one of the autoimmune diseases

Disqualifiers

Treatment with rituximab in the previous 12 months

Trial population

Patient over 18 years old. Diagnosis of one of the autoimmune diseases of interest according to the commonly accepted classification criteria for each disease, regardless of the level of disease activity.

Trial design

Design model

Other

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

670 Participants
are grouped into 18 trial groups

18

Trial groups

See each trial group below.

Group A: Myasthénie
Group B: Myopathie inflammatoire (Myosite)
Group C: Neuropathie autoimmune
Group D: Néphropathies autoimmunes
Group E: Hépatite auto-immune
Group F: Pancréatite auto-immune
Group G: Purpura Thrombopénique Immunologique
Group H: Dermatose bulleuse
Group I: Thyroïdite autoimmune
Group J: Sclérose en plaque
Group K: Sclérose latérale amyotrophique
Group L: Polyarthrite Rhumatoïde
Group M: Spondylarthrite axiale
Group N: controls
Group O: Lichen plan buccal auto-immun (LPB)
Group P: lichen plan buccal allo-immun liée à une GvHD (" Graft versus Host Disease ")
Group Q: Lupus érythémateux systémique
Group R: Sclérodermie

Trial outcomes

Primary outcomes

1

level of STIM1-PM

Membrane expression level of STIM1-PM on the surface of immune cells, measured by flow cytometry

Time frame
Day 0

Secondary outcomes

1

correlation between STIM1 expression and Clinical Score

Study of correlation between STIM1 expression on different cells and clinical scores of different autoimmune diseases or treatments received

Time frame
Day 0

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University Hospital, Brest

Lead sponsor

Source ClinicalTrials.gov
Apply now